Page last updated: 2024-09-05

sb 203580 and kallidin, des-arg(10)-

sb 203580 has been researched along with kallidin, des-arg(10)- in 1 studies

Compound Research Comparison

Studies
(sb 203580)
Trials
(sb 203580)
Recent Studies (post-2010)
(sb 203580)
Studies
(kallidin, des-arg(10)-)
Trials
(kallidin, des-arg(10)-)
Recent Studies (post-2010) (kallidin, des-arg(10)-)
3,48941,13780417

Protein Interaction Comparison

ProteinTaxonomysb 203580 (IC50)kallidin, des-arg(10)- (IC50)
B1 bradykinin receptorHomo sapiens (human)0.0009

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Davis, A; Fox, A; Ganju, P; Núñez, X; Patel, S1

Other Studies

1 other study(ies) available for sb 203580 and kallidin, des-arg(10)-

ArticleYear
p38 stress-activated protein kinase inhibitor reverses bradykinin B(1) receptor-mediated component of inflammatory hyperalgesia.
    European journal of pharmacology, 2001, Jun-15, Volume: 421, Issue:3

    Topics: Animals; Cell Line; Cyclooxygenase 2; Cytokines; Dose-Response Relationship, Drug; Enzyme Inhibitors; Hindlimb; Humans; Hyperalgesia; Imidazoles; Inflammation; Interleukin-1; Isoenzymes; Kallidin; Male; Membrane Proteins; Mitogen-Activated Protein Kinases; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Prostaglandin-Endoperoxide Synthases; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Bradykinin B1; Receptors, Bradykinin; Tumor Necrosis Factor-alpha

2001